MDNews - Lower Hudson/Bronx

May 2013

Issue link: https://viewer.e-digitaledition.com/i/125960

Contents of this Issue

Navigation

Page 7 of 43

COVER FEATURE The Multidisciplinary Tumor Board includes physicians, residents and a patient navigator. (ACS). In 2011, the FDA approved vemurafenib, a drug that targets melanoma cells with the mutated BRAF gene, along with a companion diagnostic test that identifies whether or not patients' tumors had the mutation. In approximately half of patients whose melanoma had the BRAF mutation, vemurafenib shrank the tumors and in some patients extended the period of time before tumors began growing again, thus extending those patients' lives, according to the ACS. Dr. Packer collaborates with pathologists to be certain all melanomas undergo appropriate genetic testing. Karthik Krishnamurthy, D.O., a dermatologist at Montefiore Einstein Center for Cancer Care and assistant professor, Department of Medicine (Dermatology), Albert Einstein College of Medicine, closely monitors patients following vemurafenib administration, as the drug can increase the risk of developing other types of skin cancer, such as squamous cell carcinoma and keratoacanthoma. Surgical Options for All Stages When physicians catch melanoma before it progresses and metastasizes elsewhere in the body, Katia Papalezova, M.D., a surgical oncologist, Melanoma/Sarcoma Program, Montefiore Einstein Center for Cancer Care, and assistant professor, Department of Surgery, Division of General Surgery, Albert Einstein College of Medicine, performs traditional wide local excision of the melanoma site. For "There are several treatment options for melanoma, all of which are dependent upon each patient's stage of diagnosis. Surgery is the mainstay of therapy, especially for early-stage melanoma. We also offer other advanced therapies that may be better suited to a patient's needs. We discuss all treatment options with the patient and develop the most effective course of action to manage the disease and achieve the best possible outcomes." — Katia Papalezova, M.D., surgical oncologist, Melanoma/ Sarcoma Program, Montefiore Einstein Center for Cancer Care, and assistant professor, Department of Surgery, Division of General Surgery, Albert Einstein College of Medicine 8 | Lower Hudson/Bronx MD NEWS I MDNEWS.COM melanoma that has progressed to later stages, she calls upon the full gamut of surgical options. Patients whose melanoma measures greater than 1 mm in thickness and whose lymph nodes are normal upon clinical examination are candidates for sentinel lymph node biopsy (SLNB). "A physician injects a radioactive substance directly adjacent to the melanoma or biopsy scar, as well as a blue dye," says Dr. Papalezova, who co-founded the Melanoma/Sarcoma Program with Dr. Krishnamurthy. "The dye travels along the lymph channels to the sentinel lymph node. Once identified, this lymph node is removed, and we perform a microscopic exam to determine whether cancer cells are present. If we find none, it is unlikely the cancer has spread to other lymph nodes, and usually no other treatment is necessary." If the team pathologist finds cancer in the lymph node, Dr. Papalezova discusses with the patient a procedure called complete lymph node dissection (CLND), which is offered to determine the extent of the melanoma's progression. Both SLNB and CLND are conducted to determine the subsequent course of treatment. "We offer sentinel lymph node biopsy for prognostic and staging purposes," Dr. Papalezova says. "After this procedure, we know what stage the patient's disease is, so we can then see if he or she qualifies for clinical trials, which patients in general cannot enroll in unless we assess the status of their lymph nodes." Nitin Ohri, M.D., is a radiation oncologist at the Montefiore Einstein Center for Cancer Care and assistant professor, Department of Radiation Oncology, Albert Einstein College of Medicine, who specializes in the treatment of skin cancer with radiation therapy. "Radiotherapy is often used for locally advanced skin cancers after surgery to decrease the risk of disease recurrence," Dr. Ohri says. "We also use radiotherapy as a definitive treatment for patients for whom surgery would be unsafe or yield poor cosmetic outcomes." Recent advances in target definition, treatment planning and setup verification

Articles in this issue

Links on this page

Archives of this issue

view archives of MDNews - Lower Hudson/Bronx - May 2013